The 2 analysts offering 12-month price forecasts for Sonnet Biotherapeutics Holdings Inc have a median target of 2.25, with a high estimate of 2.50 and a low estimate of 2.00. The median estimate represents a +667.92% increase from the last price of 0.29.
The current consensus among 2 polled investment analysts is to Buy stock in Sonnet Biotherapeutics Holdings Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.14
Reporting Date Aug 31
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.